RxDoctor Payments Data

Andrea Johnson

Family · Carmel, INNPI 1477294627

Payments from drug & device makers

$4,751in general payments, 2019–2025

Across 249 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$833
  • UCB, Inc.$470
  • Livanova USA, Inc.$323
  • Sumitomo Pharma America, Inc.$280
  • Pfizer$278
  • Novartis$272
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$4,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,751 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$105,261
Emgality PenGalcanezumab-Gnlm41$35,077
BriviactBrivaracetam16$24,187
Lacosamide34$4,075
Oxcarbazepine23$1,973
Levetiracetam56$1,342
Levetiracetam ErLevetiracetam11$1,166
Carbidopa-LevodopaCarbidopa/Levodopa30$781
Gabapentin59$554
Primidone15$452
Memantine Hcl14$407
Phenytoin Sodium Extended13$387
Quetiapine Fumarate15$320
Duloxetine Hcl19$285
Pregabalin15$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$200$105,26113 claims
UCB, Inc.Briviact$470$24,18716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.

Other family in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →